Posted by Michael Wonder on 25 May 2026
Novo’s Sogroya gets Korea reimbursement for growth hormone deficiency
22 May 2026 - Novo Nordisk Pharma Korea said Thursday its once weekly growth hormone therapy Sogroya has received national health insurance reimbursement in Korea for children and adults with growth hormone deficiency.
The company held a media session in Seoul to discuss the clinical value of long-acting growth hormone therapy and its use in patients who need long-term treatment.
